spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

India probes possible cough syrup link to deaths of nine children

Indian authorities said on Saturday they are investigating if contaminated cough syrup caused the deaths of nine children in a central state after a batch of the medication was found to contain dangerous levels of a toxic chemical.

The Health Ministry said samples of Coldrif Cough Syrup, manufactured by Sresan Pharma in the southern state of Tamil Nadu, were tested by state authorities and found to contain diethylene glycol (DEG) exceeding permissible limits.

DEG, a toxic solvent used in industrial products, has been linked to fatal poisoning in several countries.
The statement comes after media reports suggested that recent deaths of nine children in the central state of Madhya Pradesh could have been linked to cough syrup consumption.

The Madhya Pradesh Food and Drug Administration (MPFDA) also analysed three of 13 samples collected, which were found free of contamination, the ministry statement said.

However, Tamil Nadu’s drug regulator later confirmed DEG contamination in samples taken directly from Sresan Pharma’s manufacturing site in Kanchipuram, it said.

Sresan Pharma did not immediately respond to a request for comment sent by email.

Authorities have launched inspections of 19 drug manufacturers across six states to identify quality control lapses and recommend improvements to prevent future incidents, the ministry said.

India has faced scrutiny over the quality of its pharmaceutical exports after the World Health Organization linked cough syrups made by another company to the deaths of 70 children in Gambia in 2022 — a finding that New Delhi later disputed.

Hot this week

Novo Nordisk Lowers Full-Year Profit Guidance in New CEO’s Maiden Quarter

Wegovy-maker Novo Nordisk lowered its full-year profit forecast on...

Compass Pathways to expedite launch timing of its experimental depression therapy

Drug developer Compass Pathways said on Tuesday it is...

Pharma Investment to establish manufacturing facility at SOHAR Freezone

SOHAR Port and Freezone has signed a land lease...

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Novo Nordisk and Pfizer have revised their bids for...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img